Researching novel therapeutic strategies for neurodegenerative conditions
Preclinical research has shown that the inhibition of Usp14 activates proteasomes, tasked with protein destruction, and increases the degradation rate of aggregation-prone proteins. Number of neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease, are associated with high levels of toxic protein aggregates and generate novel therapeutic options for patients with conditions for which there are currently no adequate treatment options.
Proteostasis is researching novel Usp14 inhibitors to enhance clearance of aggregation-prone proteins, such as α-synuclein in Parkinson’s disease and tau in Alzheimer’s disease among others.
This program is developed in collaboration with Biogen. This program is fully owned by Proteostasis Therapeutics.